Company: DARE
Filing Date: 2025-11-13
Form Type: 10-Q
Source: 0001401914-25-000050
Chunk: 78

Company: Dare Bioscience, Inc.
Filing Date: 2025-11-13
Form: 10-Q
Item: Part I, Item 1
Chunk 78
---
 loss$(3,562,766)$(4,702,501)$1,139,735 (24)%Other comprehensive lossForeign currency translation adjustments6,860 22,935 (16,075)(70)%Comprehensive loss$(3,555,906)$(4,679,566)$1,123,660 (24)%

Revenues

Revenues for the three months ended September 30, 2025 and September 30, 2024 are non-cash royalty revenues related to our license agreement with Organon to commercialize XACIATO. From and after April 1, 2024, any revenue we recognize under such license agreement will be recognized as non-cash royalty revenue. See "—Financial Overview—Revenue," above for information. 

General and administrative expenses

The increase of approximately $0.5 million in G&A expenses for the three months ended September 30, 2025 as compared to the three months ended September 30, 2024 was primarily attributable to increases in professional services and commercial-readiness expenses driven by execution against our expanded business strategy.

Research and development expenses

The following table summarizes our R&D expenses for the periods indicated, together with the changes in those items in terms of dollars and percentage:

37

Three Months EndedSeptember 30,Change20252024$%Direct program costs:Ovaprene (1)$1,458,054 $1,940,537 $(482,483)(25)%Sildenafil Cream (2)417,543 (60,905)478,448 (786)%Other advanced clinical stage programs (1)699,866 164,351 535,515 326 %Phase 1 and Phase 1-ready clinical stage programs (1)269,641 91,847 177,794 194 %Preclinical stage programs (1)2,111,045 554,677 1,556,368 281 %Other development programs— 1,206 (1,206)(100)%Contra R&D expenses (3)(4,314,481)(1,152,437)(3,162,044)274 %Total direct program costs641,668 1,539,276 (897,608)(58)%Indirect costs:Personnel-related (including stock-based compensation)1,168,085 1,429,180 (261,095)(18)%Outside services (including consulting)10